FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019741587> ?p ?o ?g. }

• W2019741587 endingPage "79" @default.
• W2019741587 startingPage "75" @default.
• W2019741587 abstract "This study evaluated the efficacy of two dosage levels of enprostil in 129 patients with gastric ulcer disease. Patients with endoscopically diagnosed gastric ulcer were randomly assigned to receive enprostil 70 μg, enprostil 35 μg, or a matching placebo capsule twice daily for six weeks. Ulcer healing rates were similar in all treatment groups after two weeks of therapy, but began to show some differences in favor of the enprostil treatment groups after four weeks. Greater differences were noted after six weeks of therapy, with healing rates of 70 percent in the 70-μg enprostil group, 82 percent in the 35-μg enprostil group, and 50 percent in the placebo group. The six-week healing rate in the 35-μg enprostil group was significantly greater than the placebo rate (p=0.005). Comparison of healing rates in the active treatment groups and the placebo group after six weeks of therapy showed a correlation between therapeutic effect and ulcer size at baseline. This trends is illustrated by a 24 percent difference between the 35-μg enprostil group and the placebo group among patients with small (3 to 9 mm) ulcers, compared with a 46 percent difference between these two groups among patients with large (20 to 30 mm) ulcers. Thus, the effectiveness of enprostil is more readily demonstrable in patients with larger ulcers. This study evaluated the efficacy of two dosage levels of enprostil in 129 patients with gastric ulcer disease. Patients with endoscopically diagnosed gastric ulcer were randomly assigned to receive enprostil 70 μg, enprostil 35 μg, or a matching placebo capsule twice daily for six weeks. Ulcer healing rates were similar in all treatment groups after two weeks of therapy, but began to show some differences in favor of the enprostil treatment groups after four weeks. Greater differences were noted after six weeks of therapy, with healing rates of 70 percent in the 70-μg enprostil group, 82 percent in the 35-μg enprostil group, and 50 percent in the placebo group. The six-week healing rate in the 35-μg enprostil group was significantly greater than the placebo rate (p=0.005). Comparison of healing rates in the active treatment groups and the placebo group after six weeks of therapy showed a correlation between therapeutic effect and ulcer size at baseline. This trends is illustrated by a 24 percent difference between the 35-μg enprostil group and the placebo group among patients with small (3 to 9 mm) ulcers, compared with a 46 percent difference between these two groups among patients with large (20 to 30 mm) ulcers. Thus, the effectiveness of enprostil is more readily demonstrable in patients with larger ulcers." @default.
• W2019741587 created "2016-06-24" @default.
• W2019741587 creator A5031378150 @default.
• W2019741587 date "1986-08-01" @default.
• W2019741587 modified "2023-09-25" @default.
• W2019741587 title "Treatment of gastric ulcer with enprostil" @default.
• W2019741587 cites W1460228636 @default.
• W2019741587 cites W1485248367 @default.
• W2019741587 cites W1766265833 @default.
• W2019741587 cites W1910361119 @default.
• W2019741587 cites W1994307743 @default.
• W2019741587 cites W2001512075 @default.
• W2019741587 cites W2031124608 @default.
• W2019741587 cites W2040799617 @default.
• W2019741587 cites W2041506651 @default.
• W2019741587 cites W2063803293 @default.
• W2019741587 cites W2117216086 @default.
• W2019741587 cites W2164443169 @default.
• W2019741587 cites W96092361 @default.
• W2019741587 doi "https://doi.org/10.1016/s0002-9343(86)80016-x" @default.
• W2019741587 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3092660" @default.
• W2019741587 hasPublicationYear "1986" @default.
• W2019741587 type Work @default.
• W2019741587 sameAs 2019741587 @default.
• W2019741587 citedByCount "28" @default.
• W2019741587 crossrefType "journal-article" @default.
• W2019741587 hasAuthorship W2019741587A5031378150 @default.
• W2019741587 hasConcept C126322002 @default.
• W2019741587 hasConcept C141071460 @default.
• W2019741587 hasConcept C142724271 @default.
• W2019741587 hasConcept C204787440 @default.
• W2019741587 hasConcept C27081682 @default.
• W2019741587 hasConcept C3017583242 @default.
• W2019741587 hasConcept C71924100 @default.
• W2019741587 hasConcept C90924648 @default.
• W2019741587 hasConceptScore W2019741587C126322002 @default.
• W2019741587 hasConceptScore W2019741587C141071460 @default.
• W2019741587 hasConceptScore W2019741587C142724271 @default.
• W2019741587 hasConceptScore W2019741587C204787440 @default.
• W2019741587 hasConceptScore W2019741587C27081682 @default.
• W2019741587 hasConceptScore W2019741587C3017583242 @default.
• W2019741587 hasConceptScore W2019741587C71924100 @default.
• W2019741587 hasConceptScore W2019741587C90924648 @default.
• W2019741587 hasIssue "2" @default.
• W2019741587 hasLocation W20197415871 @default.
• W2019741587 hasLocation W20197415872 @default.
• W2019741587 hasOpenAccess W2019741587 @default.
• W2019741587 hasPrimaryLocation W20197415871 @default.
• W2019741587 hasRelatedWork W1586374228 @default.
• W2019741587 hasRelatedWork W2003938723 @default.
• W2019741587 hasRelatedWork W2047967234 @default.
• W2019741587 hasRelatedWork W2089201504 @default.
• W2019741587 hasRelatedWork W2118496982 @default.
• W2019741587 hasRelatedWork W2364998975 @default.
• W2019741587 hasRelatedWork W2369162477 @default.
• W2019741587 hasRelatedWork W2439875401 @default.
• W2019741587 hasRelatedWork W4238867864 @default.
• W2019741587 hasRelatedWork W2525756941 @default.
• W2019741587 hasVolume "81" @default.
• W2019741587 isParatext "false" @default.
• W2019741587 isRetracted "false" @default.
• W2019741587 magId "2019741587" @default.
• W2019741587 workType "article" @default.